Testicular Self-Exam Is Cost-Effective

Share this content:
Flavopiridol + FOLFOX 'Active' Against Some Late-relapse Germ Cell Tumors
Flavopiridol + FOLFOX 'Active' Against Some Late-relapse Germ Cell Tumors

(HealthDay News) -- According to two new studies, testicular self-examination is cost-effective and non-Caucasians with testicular cancer have worse outcomes. These findings were presented at the annual meeting of the American Urological Association, held from May 16 to 21 in Orlando, Fla.

Michael E. Aberger, MD, from the University of Kansas in Kansas City, and colleagues compared the average cost of treatment for a missed advanced-stage testicular tumor with that of six other scenarios related to the work-up of a testicular mass discovered during self-examination. 

RELATED: Male Reproductive Cancers Resource Center

The researchers found that the total costs for an advanced-stage seminoma or non-seminoma were $48,877 and $51,592, respectively. These costs were equivalent to 313 benign office visits; 180 visits with scrotal ultrasound; 79 visits with serial scrotal ultrasounds and laboratory testing; six office visits followed by radical inguinal orchiectomy for benign pathology; or three office visits resulting in identification, therapy, and surveillance for early-stage testicular cancer.

Claudio Jeldres, MD, from the Virginia Mason Medical Center in Seattle, and colleagues examined racial variations in outcomes for 75,902 patients with testicular germ cell tumors identified from the National Cancer Data Base. 

The researchers found that 10.6% of Caucasians presented with stage III disease, compared with 17.2%, 15.5%, and 13.9% of Hispanics, African-Americans, and Asians, respectively. The worst survival was seen for African-Americans, with a two-fold increased risk of death for African-American versus Caucasian patients with similar stage at presentation.

"Health care access, inherent biological differences, and cultural perceptions may be important factors in patient diagnosis, treatment, and survival variances," Benjamin J. Davies, MD from the University of Pittsburgh School of Medicine, said in a statement.

References

  1. Aberger ME, Wilson B, Holzbeierlein J, et al. MP10-11 TESTICULAR SELF-EXAMINATIONS: A COST ANALYSIS. J Urol. 2014;191(4): e118.
  2. Jeldres C, Nichols CR, Pham K, et al. MP10-05 INFLUENCE OF RACE ON OUTCOMES IN TESTICULAR CANCER: ANALYSIS OF 75902 PATIENTS IN THE NATIONAL CANCER DATA BASE. J Urol. 2014;191(4): e116.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs